Specifically, MASLD patients showed significantly higher serum concentrations of IL-2 (median 6.3 vs. 3.7 pg/mL, p = 0.043), IL-17A (12.4 vs. 6.0 pg/mL, p = 0.035), CXCL10 (3130 vs. 1151 pg/mL, p = 0.015), and TGF-β1 (196 vs. 100 pg/mL, p = 0.024), as well as the anti-inflammatory cytokine IL-10 (18.7 vs. 10.0 pg/mL, p = 0.046). Here, IL17A is linked to metabolic dysfunction-associated steatotic liver disease.